ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01746095
Recruitment Status : Completed
First Posted : December 10, 2012
Last Update Posted : December 9, 2014
Sponsor:
Collaborators:
Synteract, Inc.
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
Savara Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : November 2014
  Actual Study Completion Date : November 2014